INVA — Innoviva, Inc.

Innoviva (INVA) Q4 2017 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2017 Performance:
  • Net sales for RELVAR/BREO: $405.3 million (up 48% YoY)
  • U.S. net sales for BREO: $241.6 million (up 53% YoY)
  • ANORO Q4 net sales: $147.3 million (up 62% YoY)
  • Total royalties earned in Q4: $70.5 million (up 51% YoY)
  • Income from operations: $66.4 million (up 76% YoY)
  • Adjusted EBITDA: $72.3 million (up 65% YoY)
  • Net income attributable to stockholders: $58.4 million ($0.50 EPS, up 129% YoY)
• Full Year 2017 Performance:
  • Total royalties: $227.9 million
  • Income from operations: $183.6 million (up 68% YoY)
  • Adjusted EBITDA: $207.5 million (91% margin)
  • Basic EPS: $1.25 (up 131% YoY)
  • Total cash and equivalents: $129.1 million

2. Strategic Updates and Business Highlights

• Innoviva reported record high TRx market share for RELVAR/BREO and ANORO in the U.S., with significant year-over-year growth in prescription volumes (BREO: 77%, ANORO: 69%).
• The launch of TRELEGY ELLIPTA in November 2017 contributed to the portfolio, with over 3,000 TRxs recorded by year-end.
• The company is focused on maximizing market share through its collaboration with GSK and is optimistic about the potential of its products.
• Positive data from a study comparing ANORO to STIOLTO RESPIMAT was highlighted as a support for ANORO's commercialization.

3. Forward Guidance and Outlook

• Innoviva remains optimistic about continued profitability and cash generation in 2018, driven by strong underlying demand trends and favorable reimbursement status.
• The company anticipates a positive impact from the U.S. tax reform, mainly due to a reduced corporate tax rate, which could lower cash taxes once NOLs are fully utilized.
• The primary focus for 2018 will be on optimizing the commercial success and global rollout of its products.

4. Bad News, Challenges, or Points of Concern

• There were competitive pressures noted, particularly affecting the new-to-brand market share for BREO, which remained flat at 23.2% during Q4.
• The company incurred costs related to a proxy contest, which impacted basic EPS by approximately $0.08 per share in 2017.
• Despite strong overall performance, there is a need to monitor the competitive landscape and market dynamics closely.

5. Notable Q&A Insights

• The D&O insurance recovery of $2.7 million was for litigation costs incurred in prior quarters, not just Q4.
• Couponing levels for BREO and ANORO are expected to decrease as coverage improves, although couponing remains an essential tool in a competitive market.
• Initial feedback on TRELEGY from physicians is still early, with 3,000 scripts noted, but the company sees a market opportunity in the triple therapy segment for COPD.

Overall, Innoviva's Q4 2017 results reflect strong growth and a positive outlook, although the company must navigate competitive pressures and the implications of ongoing litigation costs.